VUNO said that it has signed a research contract with Mayo Clinic to jointly develop a new biomarker necessary for the diagnosis and treatment of cancer.

The company stressed that it has established a research cooperation system with the world's best cancer center.

With the accord, the two sides expect to improve artificial intelligence-based digital pathology and oncology research by using Mayo Clinic's medical data, such as radiology images, histopathology images, and genomic data.

Notably, VUNO and Mayo Clinic aim to discover biomarkers for cancer diagnosis and prognosis based on AI by starting to implement and verify AI algorithms that predict the location of primary cancer, cancer recurrence, immune treatment response, and target treatment effect.

Also, by using large-scale data that includes various institutions and races, the two plan to promote the development of precision solutions applicable in various clinical environments and present major research results at world-class conferences, such as the American Association for Cancer Research (AACR) and the American Society for Clinical Oncology (ASCO) in the future.

"The cooperation with Mayo Clinic, the world's top medical institution, is meaningful. It will help VUNO lay its foundation for improving cancer diagnosis and treatment based on its medical AI solution in the future," VUNO CTO Jeong Kyu-hwan said. "We will do our best to develop and commercialize precision medical solutions with high clinical value by focusing on our differentiated technology and research capabilities, which the company has proven through numerous global conferences and papers."